Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY II
2011-004994-94Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing MK-6072 + standard-of-care antibiotics, MK-3415A + standard-of-care antibiotics and Placebo + standard-of-care antibiotics (3 arms). Primary endpoint: Proportion of patients with CDI recurrence. Started Nov 2011; status: completed.
02
Drugs
bezlotoxumabactoxumab + bezlotoxumab
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2011-004994-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004994-94.